61 related articles for article (PubMed ID: 35102899)
1. Survival After Cryotherapy Versus Radiotherapy in Low and Intermediate Risk Localized Prostate Cancer.
Li H; Xu Z; Lv Z; Wang M; Liu M
Clin Genitourin Cancer; 2023 Dec; 21(6):679-693. PubMed ID: 37422351
[TBL] [Abstract][Full Text] [Related]
2. Trends in treatments for prostate cancer in the United States, 2010-2015.
Wang J; Xia HH; Zhang Y; Zhang L
Am J Cancer Res; 2021; 11(5):2351-2368. PubMed ID: 34094691
[TBL] [Abstract][Full Text] [Related]
3. Transperineal laser ablation (TPLA) with ultrasound/MRI fusion guidance in the treatment of localized radiotherapy-resistant prostate cancer.
Manenti G; Nezzo M; Ryan CP; Fraioli FR; Carreri B; Gigliotti PE; Angeloni C; Di Pietro F; De Angeli M; Perretta T; D'Angelillo RM; Garaci FG
BJR Open; 2023; 5(1):20230042. PubMed ID: 37942495
[TBL] [Abstract][Full Text] [Related]
4. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy versus watchful waiting for prostate cancer.
Hegarty J; Beirne PV; Walsh E; Comber H; Fitzgerald T; Wallace Kazer M
Cochrane Database Syst Rev; 2010 Nov; (11):CD006590. PubMed ID: 21069689
[TBL] [Abstract][Full Text] [Related]
6. The comparison of survival between active surveillance or watchful waiting and focal laser ablation in patients with low-risk prostate cancer.
Li JK; Zhang CC; Qiu S; Jin K; Cai BY; Yuan QM; Xiong XY; Tang LS; Jin D; Zhou XH; Bao YG; Yang L; Wei Q
Asian J Androl; 2022; 24(5):494-499. PubMed ID: 35102899
[TBL] [Abstract][Full Text] [Related]
7. The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.
Yuan QM; Lin TH; Jin K; Qiu S; Zhou XH; Jin D; Li JK; Yang L; Wei Q
Asian J Androl; 2022; 24(3):305-310. PubMed ID: 34596600
[TBL] [Abstract][Full Text] [Related]
8. Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable-risk prostate cancer.
Huang D; Ruan X; Huang J; Zhang N; Jiang G; Gao Y; Xu D; Na R
Cancer Med; 2023 Apr; 12(8):9868-9878. PubMed ID: 36727535
[TBL] [Abstract][Full Text] [Related]
9. Focal Laser Ablation Versus Radical Prostatectomy for Localized Prostate Cancer: Survival Outcomes From a Matched Cohort.
Zheng X; Jin K; Qiu S; Han X; Liao X; Yang L; Wei Q
Clin Genitourin Cancer; 2019 Dec; 17(6):464-469.e3. PubMed ID: 31594734
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
11. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
12. The real-time intraoperative guidance of the new HIFU Focal-One
Checcucci E; De Luca S; Piramide F; Garrou D; Mosca A; Galla A; Belli G; Russo F; Rescigno P; Poti C; Amparore D; Verri P; Volpi G; Manfredi M; Fiori C; Porpiglia F
J Ultrasound; 2022 Jun; 25(2):225-232. PubMed ID: 34031862
[TBL] [Abstract][Full Text] [Related]
13. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
14. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
[TBL] [Abstract][Full Text] [Related]
15. Focal irreversible electroporation for localized prostate cancer management: prospective assessment of efficacy and safety.
Enikeev D; Taratkin M; Morozov A; Shpikina A; Singla N; Gomez Rivas J; Barret E; Glybochko P
Minerva Urol Nefrol; 2020 Oct; 72(5):644-645. PubMed ID: 32638576
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
